OLD Second National Bank of Aurora Sells 290 Shares of Eli Lilly and Company (LLY)

OLD Second National Bank of Aurora lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,517 shares of the company’s stock after selling 290 shares during the period. OLD Second National Bank of Aurora’s holdings in Eli Lilly and were worth $948,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of LLY. Washington Trust Bank raised its position in shares of Eli Lilly and by 92.8% in the first quarter. Washington Trust Bank now owns 10,369 shares of the company’s stock worth $872,000 after buying an additional 4,990 shares in the last quarter. Pinnacle Bank purchased a new position in shares of Eli Lilly and during the first quarter worth approximately $458,000. Juncture Wealth Strategies LLC raised its position in shares of Eli Lilly and by 6.9% in the first quarter. Juncture Wealth Strategies LLC now owns 3,100 shares of the company’s stock worth $261,000 after buying an additional 200 shares in the last quarter. Peoples Financial Services CORP. raised its position in shares of Eli Lilly and by 4.1% in the first quarter. Peoples Financial Services CORP. now owns 16,700 shares of the company’s stock worth $1,404,000 after buying an additional 655 shares in the last quarter. Finally, CHICAGO TRUST Co NA raised its position in shares of Eli Lilly and by 5.6% in the first quarter. CHICAGO TRUST Co NA now owns 3,607 shares of the company’s stock worth $304,000 after buying an additional 192 shares in the last quarter. Institutional investors and hedge funds own 75.59% of the company’s stock.

Shares of Eli Lilly and Company (LLY) traded down 0.94% during midday trading on Friday, hitting $77.07. 4,061,282 shares of the company were exchanged. The stock has a market cap of $81.31 billion, a PE ratio of 33.35 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72. The stock’s 50-day moving average is $82.39 and its 200-day moving average is $81.90.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the company posted $0.86 EPS. Equities research analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.

LLY has been the topic of a number of recent analyst reports. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $92.00 price objective on shares of Eli Lilly and in a report on Tuesday, May 16th. BMO Capital Markets set a $71.00 price objective on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, April 25th. Argus lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a report on Monday, July 17th. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of Eli Lilly and in a report on Tuesday, May 30th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $88.27.

In related news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the sale, the vice president now owns 62,056 shares in the company, valued at approximately $4,962,618.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the sale, the insider now owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock valued at $55,845,287 in the last quarter. 0.20% of the stock is currently owned by corporate insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.